MagicTouch: Sirolimus Drug Coated Balloon Catheter
MagicTouch - Concept Medical - Developing technologies for drug delivery with a strong emphasis on intellectual property.

Novel, First of its kind Sirolimus drug coated balloon catheter for the treatment coronary artery disease

MagicTouch is intended for in-stent restenosis, small vessels, bifurcation lesions and de-novo lesions

Sirolimus Coated

Balloon Catheter

MagicTouch

Assuring Safety by Delivering Sirolimus

  • TECHNOLOGY - MagicTouch

    TECHNOLOGY

    An innovative proprietary Nanolute technology providing better bioavailability of SIROLIMUS

  • COATING - MagicTouch

    COATING

    Unique coating technology leads to 100% balloon surface coating

  • DRUG - MagicTouch

    DRUG

    Sirolimus: A drug with proven safety profile

  • CARRIER - MagicTouch

    CARRIER

    A biocompatible phospholipid drug carrier improving the adhesion property of Sirolimus

Nanolute Technology

NANOLUTE TECHNOLOGY is designed to improve the lipophilicity and bioavailability of Sirolimus

  • Phospholipid is a drug carrier with two lipophilic tails and one hydrophilic head.
  • Sirolimus is encapsulated in phospholipid with proprietary Nanolute technology.

Know More

Unique Coating Technology

Drug carrier along with drug is coated on the unfolded balloon to achieve 100% coating on balloon surface
Unique and proprietary refolding mechanism facilitates better crossing profile

TECHNICAL SPECIFICATION

DRUG/EXCIPIENT
Drug Sirolimus
Drug Dose 1.27µg/mm²
Drug Carrier Phospholipid Based Excipient
Balloon
Balloon Material Polyamide
Catheter design Rapid Exchange(RX) Design
Delivery system
Shaft Diameter – Proximal 1.7 F
Shaft Diameter – Distal 2.5 F
Usable Catheter Length 140 cm
Tip Profile 0.016”
Nominal Pressure 6 bar
Rated Burst Pressure 16 bar (14 bar for 4.00/ 25 to 40 mm)
Guiding Catheter Compatibility 5F
Guidewire Compatibility 0.014” maximum recommended

ORDERING INFORMATION

Diameter/Length 10 mm 15 mm 20 mm 25 mm 30 mm 35 mm 40 mm
1.50 mm CMT15010 CMT15015 CMT15020 CMT15025 CMT15030 CMT15035 CMT15040
2.00 mm CMT20010 CMT20015 CMT20020 CMT20025 CMT20030 CMT20035 CMT20040
2.25 mm CMT22510 CMT22515 CMT22520 CMT22525 CMT22530 CMT22535 CMT22540
2.50 mm CMT25010 CMT25015 CMT25020 CMT25025 CMT25030 CMT25035 CMT25040
2.75 mm CMT27510 CMT27515 CMT27520 CMT27525 CMT27530 CMT27535 CMT27540
3.00 mm CMT30010 CMT30015 CMT30020 CMT30025 CMT30030 CMT30035 CMT30040
3.50 mm CMT35010 CMT35015 CMT35020 CMT35025 CMT35030 CMT35035 CMT35040
4.00 mm CMT40010 CMT40015 CMT40020 CMT40025 CMT40030 CMT40035 CMT40040

Talk to a representative
Fill out a quick form and our representatives will be in touch.


MagicTouch

Clinical Programs

MORE THAN 3,000 PATIENTS ENROLED AND PLANNED

Sr. No Study Name Type of Study Target Patients Country Principal Investigator
Sr. No:  1 Study Name:   Nanolute Type of Study:  Prospective, Multi-Center, Real world Target Patients:  450 Patients Country:  India Principal Investigator:  Dr. Sameer Dani
Sr. No:  2 Study Name:   FASICO Type of Study:  Prospective, Single arm, Single-center Target Patients:  32 Patients Country:  Italy Principal Investigator:  Dr. Bernardo Cortese
Sr. No:  3 Study Name:   Brazil-FIM Type of Study:  Prospective, Multi-Center, Non-randomised, First-In-Man Target Patients:  30 Patients Country:  Brazil Principal Investigator:  Dr. Alexandre Abizaid
Sr. No:  4 Study Name:   EASTBOURNE Type of Study:  Prospective, Multi-Center, spontaneous clinical registry Target Patients:  2,000 Patients Country:  Global Principal Investigator:  Dr. Bernardo Cortese
Sr. No:  5 Study Name:   UK-SEB REGISTRY Type of Study:  Spontaneous, Clinical, Observational trial Target Patients:  500 Patients Country:  UK Principal Investigator:  Dr. Sandeep Basavarajaiah
Sr. No:  6 Study Name:   Transform I Type of Study:  Prospective, randomized , Multi-Center study Target Patients:  114 Patients Country:  Italy and UK Principal Investigator:  Prof. Antonio Colombo

* Cardiovascular Revascularization Medicine. 2017 Oct 1;18(7):487-91. Journal of Cardiovascular Medicine. 2019 Jul 1;20(7):471-6.)

“Confidence through evidence”
Get in Touch